Psoriasis is a chronic inflammatory condition affecting 1 - 3% of the world's population. Despite the availability of several agents, therapeutic options remain limited. With a better understanding of the pathophysiology of psoriasis, several potential therapeutic targets have been identified. Peroxisome proliferator activated receptors have been shown to play a role in cutaneous homeostasis. This review focuses on the potential therapeutic role of peroxisome proliferator activated receptor-gamma agonists in psoriasis and the possibility for the future prospects.